“Synthetic biology in its broadest form encompasses a large part of the work that’s being done in biomedicine. That is, how we first understand organisms, but then use that understanding to program them or direct them to do different things,” said Dr. Lloyd Minor, dean of the School of Medicine and vice president for medical affairs at Stanford University. “And I do think that it offers a huge amount of potential across the board,” he said.
“The challenge in biology is that it is not terribly difficult to engineer organisms, to engineer living systems, to do things that can potentially be very harmful. So how do we think about monitoring, regulation, safe oversight in the biology world,” he said.
“It is collapsing time and expanding the aperture by which we are able to run experiments on a broader set of designs that scientists want to test on.” — Jennifer Lum, co-founder of Biospring Partners
Synthetic biology companies see opportunities for artificial intelligence throughout the product-development life cycle from initial design, where scientists can examine and factor in a greater number of variables and options, to the build phase to testing, where scientists can leverage the predictive nature of AI to quickly determine results.
Read entire article